SHIELD THERAPEUTICS PLC

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +145.9%

  £9,781,715 → £24,056,216

• Cash

  -53.2%

  £10,426,852 → £4,877,028

• Net assets

  -108.8%

  £11,237,946 → -£984,526

• Employees

  +5.5%

  73 → 77

• Operating profit

  +27%

  -£23,421,544 → -£17,098,752

• Profit before tax

  +18%

  -£24,201,988 → -£19,851,985

• Wages

  -0.2%

  £8,953,428 → £8,939,972

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

UK-adopted IFRS

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the above factors, the Directors believe that it remains appropriate to prepare the financial statements on a going concern basis.”

Group structure

1. SHIELD THERAPEUTICS PLC · parent
   1. Phosphate Therapeutics Limited 1% · United Kingdom
   2. Shield TX (Switzerland) AG 1% · Switzerland
   3. Shield Therapeutics Inc 1% · U.S.
   4. Shield TX (UK) Limited 1% · United Kingdom

Significant events

• “153% year-on-year growth in U.S. ACCRUFER® revenues”
• “c.$31M in financings”
• “Health Canada approval”
• “Succesful pediatric trial (Phase 3) in ID/IDA”
• “Regulatory submission in South Korea and fully recruited Phase 3 trial in China”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

7

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.